Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
DUBLIN, Ireland, Dec. 22, 2016 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it plans to present at the 35th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief executive officer, will present at 7:30 a.m. Pacific Time on January 10, 2017.
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available following the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
